Carlos Stahlhut, A. Maciag, Kyle A Sullivan, Kanchan Singh, Nadege Gitego, Zuhui Zhang, Albert H. Chan, Alok K. Sharma, Patrick A Alexander, Jin Shu, Yue Yang, Megan Rigby, R. Ma, Saman Setoodeh, Brian P Smith, Jun Pei, Dana Rabara, Erik K. Larsen, David M Turner, Cathy Zhang, Cindy Feng, S. Feng, J. Stice, R. Xu, Ken Lin, Andrew G Stephen, F. Lightstone, Chunmei Ji, Keshi Wang, D. Simanshu, D. Nissley, Eli Wallace, Bin Wang, Kerstin W. Sinkevicius, F. McCormick, P. Beltran
2026.3.6Cancer Discovery
Abstract
The pan-KRAS inhibitor BBO-11818 targets multiple oncogenic KRAS mutants in both active and inactive states, demonstrating strong biochemical, cellular, and in vivo antitumor activity.
Citation format
STAHLHUT, Carlos, et al. Discovery of BBO-11818, a potent and selective noncovalent inhibitor of (ON) and (OFF) KRAS with activity against multiple oncogenic mutants. Cancer Discovery, 2026, 16(4): 740–759.